Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb;43(2):601-612.
doi: 10.1002/hed.26515. Epub 2020 Oct 27.

Development of a multiomics database for personalized prognostic forecasting in head and neck cancer: The Big Data to Decide EU Project

Stefano Cavalieri  1 , Loris De Cecco  2 , Ruud H Brakenhoff  3 , Mara Serena Serafini  2 , Silvana Canevari  4 , Silvia Rossi  5 , Davide Lanfranco  5 , Frank J P Hoebers  6 , Frederik W R Wesseling  6 , Simon Keek  7 , Kathrin Scheckenbach  8 , Davide Mattavelli  9 , Thomas Hoffmann  10 , Laura López Pérez  11 , Giuseppe Fico  11 , Marco Bologna  12 , Irene Nauta  3 , C René Leemans  3 , Annalisa Trama  13 , Thomas Klausch  14 , Johannes Hans Berkhof  14 , Vasilis Tountopoulos  15 , Ron Shefi  16 , Luca Mainardi  12 , Franco Mercalli  17 , Tito Poli  5 , Lisa Licitra  1   18 ; BD2Decide Consortium
Affiliations

Development of a multiomics database for personalized prognostic forecasting in head and neck cancer: The Big Data to Decide EU Project

Stefano Cavalieri et al. Head Neck. 2021 Feb.

Abstract

Background: Despite advances in treatments, 30% to 50% of stage III-IV head and neck squamous cell carcinoma (HNSCC) patients relapse within 2 years after treatment. The Big Data to Decide (BD2Decide) project aimed to build a database for prognostic prediction modeling.

Methods: Stage III-IV HNSCC patients with locoregionally advanced HNSCC treated with curative intent (1537) were included. Whole transcriptomics and radiomics analyses were performed using pretreatment tumor samples and computed tomography/magnetic resonance imaging scans, respectively.

Results: The entire cohort was composed of 71% male (1097)and 29% female (440): oral cavity (429, 28%), oropharynx (624, 41%), larynx (314, 20%), and hypopharynx (170, 11%); median follow-up 50.5 months. Transcriptomics and imaging data were available for 1284 (83%) and 1239 (80%) cases, respectively; 1047 (68%) patients shared both.

Conclusions: This annotated database represents the HNSCC largest available repository and will enable to develop/validate a decision support system integrating multiscale data to explore through classical and machine learning models their prognostic role.

Keywords: big data; head and neck cancer; prognostic models; radiomics; transcriptomics.

PubMed Disclaimer

Conflict of interest statement

Yes Author Lisa Licitra has disclosed funding (to her institution) for clinical studies and research from AstraZeneca, Boehringer Ingelheim, Eisai, Merck Serono, MSD, Novartis, and Roche, has received compensation for service as a consultant/advisor and/or for lectures from AstraZeneca, Bayer, Bristol‐Myers Squibb, Boehringer Ingelheim, Debiopharm, Eisai, Merck Serono, MSD, Novartis, Roche, and Sobi; and has received travel coverage for meetings from Bayer, Bristol‐Myers Squibb, Debiopharm, Merck Serono, MSD, and Sobi. Author Ron Shefi (and the additional person Avner Algom, acknowledged within the “BD2Decide Consortium”) is employed by the company All‐In‐Image Ltd, Israel. Author Vasilis Tountopoulos (and the additional person Thanasis Dalianis, acknowledged within the “BD2Decide Consortium”) is employed by the company Technical Implementation, Innovation Lab, Athens Technology Center, Greece. Author Franco Mercalli (and the additional person Sergio Copelli, acknowledged within the “BD2Decide Consortium”) is employed by the company MultiMed Engineers, Parma, Italy. Stefan Wesarg, acknowledged within the “BD2Decide Consortium”, is employed by the company Fraunhofer, Munich, Germany. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
DSFS (A) and OS (B) in p16‐negative HNSCC patients. Left panels: DSFS and OS; central panels: survival according to TNM7; right panels: survival according to TNM8 [Color figure can be viewed at wileyonlinelibrary.com]
FIGURE 2
FIGURE 2
DSFS (A) and OS (B) in p16‐positive OPC patients. Left panels: DSFS and OS; central panels: survival according to TNM7; right panels: survival according to TNM8 [Color figure can be viewed at wileyonlinelibrary.com]
FIGURE 3
FIGURE 3
Available data in the BD2Decide final database [Color figure can be viewed at wileyonlinelibrary.com]
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394‐424. 10.3322/caac.21492. - DOI - PubMed
    1. Cramer JD, Burtness B, Le QT, Ferris RL. The changing therapeutic landscape of head and neck cancer. Nat Rev Clin Oncol. 2019;16(11):669‐683. 10.1038/s41571-019-0227-z. - DOI - PubMed
    1. Lo Nigro C, Denaro N, Merlotti A, Merlano M. Head and neck cancer: improving outcomes with a multidisciplinary approach. Cancer Manag Res. 2017;9:363‐371. 10.2147/CMAR.S115761. - DOI - PMC - PubMed
    1. Sobin LH, MK WC Gospodarowicz. TNM classification of malignant tumors. 7th ed Oxford: Wiley‐Blackwell; 2010:349–445. doi:10.1016/B978-1-4377-0272-9.50014-0 - DOI
    1. Mehra R, Ang KK, Burtness B. Management of human papillomavirus‐positive and human papillomavirus‐negative head and neck cancer. Semin Radiat Oncol. 2012;22(3):194‐197. 10.1016/j.semradonc.2012.03.003. - DOI - PubMed

Publication types

MeSH terms